Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 7.360
Filtrer
1.
Drug Res (Stuttg) ; 74(6): 255-268, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38968949

RÉSUMÉ

This comprehensive review endeavors to illuminate the nuanced facets of linalool, a prominent monoterpene found abundantly in essential oils, constituting a massive portion of their composition. The biomedical relevance of linalool is a key focus, highlighting its therapeutic attributes observed through anti-nociceptive effects, anxiolytic properties, and behavioral modulation in individuals affected by dementia. These findings underscore the compound's potential application in biomedical applications. This review further explores contemporary formulations, delineating the adaptability of linalool in nano-emulsions, microemulsions, bio-capsules, and various topical formulations, including topical gels and lotions. This review covers published and granted patents between 2018-2024 and sheds light on the evolving landscape of linalool applications, revealing advancements in dermatological, anti-inflammatory, and antimicrobial domains.


Sujet(s)
Monoterpènes acycliques , Humains , Monoterpènes acycliques/pharmacologie , Monoterpènes acycliques/usage thérapeutique , Monoterpènes acycliques/composition chimique , Anti-inflammatoires/usage thérapeutique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/administration et posologie , Animaux , Anti-infectieux/usage thérapeutique , Anti-infectieux/pharmacologie , Anxiolytiques/usage thérapeutique , Anxiolytiques/pharmacologie , Analgésiques/usage thérapeutique , Analgésiques/pharmacologie , Brevets comme sujet , Émulsions , Huile essentielle/usage thérapeutique , Huile essentielle/pharmacologie , Huile essentielle/composition chimique , Produits dermatologiques/usage thérapeutique , Produits dermatologiques/pharmacologie , Produits dermatologiques/administration et posologie
2.
Nutrients ; 16(13)2024 Jun 23.
Article de Anglais | MEDLINE | ID: mdl-38999746

RÉSUMÉ

INTRODUCTION: Myo-inositol (MI) is the most abundant inositol found in nature. To date MI supplementation is reported to be effective in the treatment of polycystic ovary syndrome, it is also suggested to alleviate the symptoms of diabetes and neurodegenerative disorders, but to date no statistically significant effects of inositol on depressive and anxiety symptoms were proven. In the study of anxiolytic effects in zebrafish, we often use the thigmotaxis index measuring the ratio of the amount of time the animal spends near the walls compared to the entire arena. AIM: The objective of this paper was to examine the effect of MI on zebrafish embryos' locomotor activity, as well as its potential anxiolytic activity in zebrafish larvae. MATERIAL AND METHODS: In the first part of the experiment, the embryos were incubated with 5, 10, 20, and 40 mg/mL MI. 1-day post fertilization, embryo mobility was evaluated and burst activity was calculated. In the next part of the study, the behavior of 5-day-old larvae was tested. RESULTS: Tests on embryo movement showed an increase in burst activity in the MI group at concentrations of 40 mg/mL (p < 0.0001) and a slight decrease in the group at concentrations of 10 mg/mL (p < 0.05). MI in the light/dark challenge had no impact on the thigmotaxis index. CONCLUSIONS: MI was shown to not affect stress reduction in zebrafish larvae. Further research on the potential of MI and other stereoisomers is needed.


Sujet(s)
Anxiolytiques , Comportement animal , Inositol , Danio zébré , Animaux , Inositol/pharmacologie , Inositol/administration et posologie , Anxiolytiques/pharmacologie , Comportement animal/effets des médicaments et des substances chimiques , Embryon non mammalien/effets des médicaments et des substances chimiques , Larve/effets des médicaments et des substances chimiques , Locomotion/effets des médicaments et des substances chimiques , Anxiété/traitement médicamenteux
3.
Drug Des Devel Ther ; 18: 2227-2248, 2024.
Article de Anglais | MEDLINE | ID: mdl-38882046

RÉSUMÉ

Purpose: The Baihe Dihuang decoction (BDD) is a representative traditional Chinese medicinal formula that has been used to treat anxiety disorders for thousands of years. This study aimed to reveal mechanisms of anxiolytic effects of BDD with multidimensional omics. Methods: First, 28-day chronic restraint stress (CRS) was used to create a rat model of anxiety, and the open field test and elevated plus maze were used to assess anxiety-like behavior. Enzyme-linked immunosorbent assay (ELISA), hematoxylin-eosin staining, and immunofluorescence staining were used to evaluate inflammatory response. Besides, 16S rRNA gene sequencing assessed fecal microbiota composition and differential microbiota. Non-targeted metabolomics analysis of feces was performed to determine fecal biomarkers, and targeted metabolomics was used to observe the levels of hippocampus neurotransmitters. Finally, Pearson correlation analysis was used to examine relationships among gut microbiota, fecal metabolites, and neurotransmitters. Results: BDD significantly improved anxiety-like behaviors in CRS-induced rats and effectively ameliorated hippocampal neuronal damage and abnormal activation of hippocampal microglia. It also had a profound effect on the diversity of microbiota, as evidenced by significant changes in the abundance of 10 potential microbial biomarkers at the genus level. Additionally, BDD led to significant alterations in 18 fecal metabolites and 12 hippocampal neurotransmitters, with the majority of the metabolites implicated in amino acid metabolism pathways such as D-glutamine and D-glutamate, alanine, arginine and proline, and tryptophan metabolism. Furthermore, Pearson analysis showed a strong link among gut microbiota, metabolites, and neurotransmitters during anxiety and BDD treatment. Conclusion: BDD can effectively improve anxiety-like behaviors by regulating the gut-brain axis, including gut microbiota and metabolite modification, suppression of hippocampal neuronal inflammation, and regulation of neurotransmitters.


Sujet(s)
Anxiolytiques , Modèles animaux de maladie humaine , Médicaments issus de plantes chinoises , Microbiome gastro-intestinal , Métabolomique , Rat Sprague-Dawley , Animaux , Rats , Anxiolytiques/pharmacologie , Médicaments issus de plantes chinoises/pharmacologie , Mâle , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Stress psychologique/traitement médicamenteux , Stress psychologique/métabolisme , Anxiété/traitement médicamenteux , Anxiété/métabolisme , Contention physique , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme
4.
Commun Biol ; 7(1): 728, 2024 Jun 14.
Article de Anglais | MEDLINE | ID: mdl-38877285

RÉSUMÉ

Benzodiazepines, commonly used for anxiolytics, hinder conditioned fear extinction, and the underlying circuit mechanisms are unclear. Utilizing remimazolam, an ultra-short-acting benzodiazepine, here we reveal its impact on the thalamic nucleus reuniens (RE) and interconnected hippocamposeptal circuits during fear extinction. Systemic or RE-specific administration of remimazolam impedes fear extinction by reducing RE activation through A type GABA receptors. Remimazolam enhances long-range GABAergic inhibition from lateral septum (LS) to RE, underlying the compromised fear extinction. RE projects to ventral hippocampus (vHPC), which in turn sends projections characterized by feed-forward inhibition to the GABAergic neurons of the LS. This is coupled with long-range GABAergic projections from the LS to RE, collectively constituting an overall positive feedback circuit construct that promotes fear extinction. RE-specific remimazolam negates the facilitation of fear extinction by disrupting this circuit. Thus, remimazolam in RE disrupts fear extinction caused by hippocamposeptal intermediation, offering mechanistic insights for the dilemma of combining anxiolytics with extinction-based exposure therapy.


Sujet(s)
Benzodiazépines , Extinction (psychologie) , Peur , Hippocampe , Noyaux médians du thalamus , Peur/effets des médicaments et des substances chimiques , Animaux , Benzodiazépines/pharmacologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/physiologie , Hippocampe/métabolisme , Extinction (psychologie)/effets des médicaments et des substances chimiques , Mâle , Noyaux médians du thalamus/effets des médicaments et des substances chimiques , Noyaux médians du thalamus/physiologie , Noyaux médians du thalamus/métabolisme , Rats , Anxiolytiques/pharmacologie , Souris
5.
Drug Des Devel Ther ; 18: 2143-2167, 2024.
Article de Anglais | MEDLINE | ID: mdl-38882045

RÉSUMÉ

Over the past decade, the idea of targeting the endocannabinoid system to treat anxiety disorders has received increasing attention. Previous studies focused more on developing cannabinoid receptor agonists or supplementing exogenous cannabinoids, which are prone to various adverse effects due to their strong pharmacological activity and poor receptor selectivity, limiting their application in clinical research. Endocannabinoid hydrolase inhibitors are considered to be the most promising development strategies for the treatment of anxiety disorders. More recent efforts have emphasized that inhibition of two major endogenous cannabinoid hydrolases, monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), indirectly activates cannabinoid receptors by increasing endogenous cannabinoid levels in the synaptic gap, circumventing receptor desensitization resulting from direct enhancement of endogenous cannabinoid signaling. In this review, we comprehensively summarize the anxiolytic effects of MAGL and FAAH inhibitors and their potential pharmacological mechanisms, highlight reported novel inhibitors or natural products, and provide an outlook on future directions in this field.


Sujet(s)
Amidohydrolases , Anxiolytiques , Endocannabinoïdes , Antienzymes , Acylglycerol lipase , Humains , Anxiolytiques/pharmacologie , Anxiolytiques/composition chimique , Amidohydrolases/antagonistes et inhibiteurs , Amidohydrolases/métabolisme , Acylglycerol lipase/antagonistes et inhibiteurs , Acylglycerol lipase/métabolisme , Animaux , Endocannabinoïdes/métabolisme , Antienzymes/pharmacologie , Antienzymes/composition chimique , Troubles anxieux/traitement médicamenteux , Troubles anxieux/métabolisme
6.
Behav Pharmacol ; 35(5): 303-314, 2024 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-38869060

RÉSUMÉ

Riparin A is a synthetic form of natural riparins. Acute scale studies that take into consideration the structure-activity relationship have shown preliminary evidence of antidepressant and anxiolytic effects of riparin A, similar to that already known for other riparins. However, for better pharmacological characterization of this new compound, further studies are required. The aim of this work was to evaluate the effect of chronic treatment with riparin A (10 mg/kg; intraperitoneally) on depressive-like behavior in the forced swimming test and tail suspension test, as well as the reduction of anhedonia in the sucrose preference test, and on anxiety-like behavior in the open field and elevated plus maze apparatus, triggered in rats previously subjected to unpredictable chronic mild stress by 4 weeks. In addition, a pentobarbital-induced sleep time test was also used. Riparin A reduced the duration of immobility in both the forced swimming test and tail suspension test, as well as attenuated the anhedonia in the sucrose preference test. Furthermore, riparin A appears to produce anxiolytic effects in rats exposed to an open field and elevated plus maze, while increasing the alertness/vigilance in rats submitted to pentobarbital-induced sleep time test, without altering their locomotor integrity. Our results suggest that chronic riparin A appears to be a potential pharmacological target for new studies on the control of depression- and anxiety-like behaviors in stressed rats.


Sujet(s)
Antidépresseurs , Anxiété , Dépression , Modèles animaux de maladie humaine , Rat Wistar , Animaux , Antidépresseurs/pharmacologie , Mâle , Dépression/traitement médicamenteux , Rats , Anxiété/traitement médicamenteux , Anxiolytiques/pharmacologie , Comportement animal/effets des médicaments et des substances chimiques , Natation/psychologie , Anhédonie/effets des médicaments et des substances chimiques , Stress psychologique/traitement médicamenteux , Suspension des membres postérieurs , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Souris , Test en champ ouvert/effets des médicaments et des substances chimiques
7.
Neurosci Biobehav Rev ; 163: 105741, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38838875

RÉSUMÉ

Anxiety disorders constitute a spectrum of psychological conditions affecting millions of individuals worldwide, imposing a significant health burden. Historically, the development of anxiolytic medications has been largely focused on neurotransmitter function and modulation. However, in recent years, neurolipids emerged as a prime target for understanding psychiatric pathogenesis and developing novel medications. Neurolipids influence various neural activities such as neurotransmission and cellular functioning, as well as maintaining cell membrane integrity. Therefore, this review aims to elucidate the alterations in neurolipids associated with an anxious mental state and explore their potential as targets of novel anxiolytic medications. Existing evidence tentatively associates dysregulated neurolipid levels with the etiopathology of anxiety disorders. Notably, preclinical investigations suggest that several neurolipids, including endocannabinoids and polyunsaturated fatty acids, may hold promise as potential pharmacological targets. Overall, the current literature tentatively suggests the involvement of lipids in the pathogenesis of anxiety disorders, hinting at potential prospects for future pharmacological interventions.


Sujet(s)
Troubles anxieux , Humains , Troubles anxieux/traitement médicamenteux , Troubles anxieux/métabolisme , Animaux , Endocannabinoïdes/métabolisme , Anxiolytiques/pharmacologie , Anxiolytiques/usage thérapeutique , Métabolisme lipidique/physiologie , Métabolisme lipidique/effets des médicaments et des substances chimiques
8.
J Ethnopharmacol ; 333: 118476, 2024 Oct 28.
Article de Anglais | MEDLINE | ID: mdl-38908491

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Sugarcane (Saccharum officinarum L.) is reported by traditional medicine as tonic, stimulating and beneficial in increasing resistance to fatigue. Previous preclinical studies in rats using aqueous extract of sugarcane leaves (AE) revealed pharmacological effects on the central nervous and cardiovascular systems involving the participation of dopaminergic pathways. This neurotransmission system is also related to motor, emotional and cognitive activities, which could, in part, justify the ethnopharmacological information. AIM OF STUDY: The present study aimed to investigate the motor, emotional and cognitive activities of rats submitted to AE treatment using behavioral tests in order to correlate the pharmacological effects with the therapeutic benefits postulated by traditional medicine. Additionally, the chemical profile of AE was evaluated by HPLC-UV/Vis, and the presence of shikimic acid, vitexin, and ferulic acid, as possible chemical markers, was investigated through comparisons of chemical parameters with the authentic patterns, and a UV-Vis scan of known spectra. MATERIAL AND METHODS: Rats received water (1.5 mL/kg, p.o.) and AE (0.5, 10 and 500 mg/kg, p.o.) in the absence and presence of haloperidol (0.5 mg/kg, i.p.), 90 min before open field; rotarod; elevated plus maze and inhibitory avoidance tests for investigation of motor; emotional and cognitive responses. As a positive control was used apomorphine (0.25 mg/kg, s.c.). The chemical profile of AE was evaluated by HPLC-UV/Vis and the presence of shikimic acid, vitexin and ferulic acid, as possible chemical markers, was investigated through comparisons with the retention times, an increase of the integral of the peak area determined by co-injection of AE with the authentic patterns, and a UV-Vis scan of known spectra. RESULTS: In open field, it revealed that AE increased locomotion; reduced rearing but did not change freezing and grooming. Besides, AE increased motor performance in rotarod and reduced anxiety in elevated plus maze. A relation dose-response was observed in these tests where the lowest dose of AE was more effective in developing pharmacological responses. Previous administration of haloperidol inhibited the responses of AE. Inhibitory avoidance test revealed that AE did not modify fast-learning and associative memory. CONCLUSIONS: Sugarcane induced psychostimulant, anxiolytic-like effects, and improvement of motor performance in rats, with the involvement of dopaminergic pathways. The present study points to AE as a potential adaptogen but, in addition to behavioral assessments, metabolic and molecular aspects, that involve the participation of a variety of regulatory systems, will be investigated in futures studies. Phytochemical analyses showed that AE is a complex matrix and revealed shikimic acid, vitexin, and ferulic acid as potential chemical markers.


Sujet(s)
Anxiolytiques , Activité motrice , Extraits de plantes , Rat Wistar , Saccharum , Animaux , Saccharum/composition chimique , Anxiolytiques/pharmacologie , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Mâle , Rats , Activité motrice/effets des médicaments et des substances chimiques , Stimulants du système nerveux central/pharmacologie , Feuilles de plante/composition chimique , Comportement animal/effets des médicaments et des substances chimiques , Halopéridol/pharmacologie , Anxiété/traitement médicamenteux , Relation dose-effet des médicaments , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques
9.
Nutrients ; 16(10)2024 May 18.
Article de Anglais | MEDLINE | ID: mdl-38794765

RÉSUMÉ

In the process of validating the elevated zero maze, a common test of anxiety-like behavior, in our laboratory, we demonstrated an anxiolytic-like effect of castor oil and its primary component, ricinoleic acid. We tested the effects of vehicle and chlordiazepoxide in male mice in the elevated zero maze following a 30-min pretreatment time. Chlordiazepoxide is a United States Food and Drug Administration-approved drug that was previously shown to exert anxiolytic-like effects in both the elevated zero maze and elevated plus maze. Chlordiazepoxide was administered at doses of 5 or 10 mg/kg. We used 5% polyoxyl 35 castor oil (Kolliphor® EL) and saline as treatment vehicles and found that the effect of chlordiazepoxide on open zone occupancy and open zone entries was blunted when 5% Kolliphor was used as the vehicle. These tests demonstrated that chlordiazepoxide increased open zone occupancy and entries in the elevated zero maze more effectively when saline was used as the treatment vehicle and that Kolliphor dampened the anxiolytic-like effect of chlordiazepoxide when it was used as the treatment vehicle. Notably, 5% Kolliphor alone slightly increased baseline open zone occupancy and entries. Given that Kolliphor is a derivative of castor oil, we next tested the effect of 5% castor oil and 5% ricinoleic acid, which is a major component of castor oil. We found that both castor oil and ricinoleic acid increased open zone occupancy but not entries compared with saline. Altogether, our findings demonstrate that Kolliphor, castor oil, and ricinoleic acid may exert anxiolytic-like effects in male mice in the elevated zero maze. This potential anxiolytic-like effect of castor oil is consistent with its well-established beneficial effects, including anti-inflammatory, antioxidant, antifungal, and pain-relieving properties.


Sujet(s)
Anxiolytiques , Anxiété , Huile de ricin , Acide ricinoléique , Animaux , Acide ricinoléique/pharmacologie , Anxiolytiques/pharmacologie , Mâle , Souris , Anxiété/traitement médicamenteux , Comportement animal/effets des médicaments et des substances chimiques , Chlordiazépoxyde/pharmacologie , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Comportement d'exploration/effets des médicaments et des substances chimiques
10.
Bull Exp Biol Med ; 176(5): 581-584, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38724817

RÉSUMÉ

A bradykinin B1 receptors antagonist PAV-0056, an 1,4-benzodiazepin-2-one derivative, intragastrically administrated to mice at doses of 0.1 and 1 mg/kg causes analgesia in the "formalin test" not inferior to that of diclofenac sodium (10 mg/kg) and tramadol (20 mg/kg). PAV-0056 at doses of 0.1 and 10 mg/kg has no anxiolytic and central muscle relaxant effects in mice and does not damage the gastric mucosa in rats. Based on the results of the conditioned place preference test, PAV-0056 also does not induce addiction in mice.


Sujet(s)
Analgésiques , Animaux , Souris , Rats , Mâle , Analgésiques/pharmacologie , Diclofenac/pharmacologie , Tramadol/pharmacologie , Psychoanaleptiques/pharmacologie , Bradykinine/analogues et dérivés , Bradykinine/pharmacologie , Anxiolytiques/pharmacologie , Antagonistes du récepteur B1 de la bradykinine/pharmacologie , Rat Wistar , Muqueuse gastrique/effets des médicaments et des substances chimiques , Muqueuse gastrique/métabolisme , Mesure de la douleur/effets des médicaments et des substances chimiques , Mesure de la douleur/méthodes
11.
Pharmacol Biochem Behav ; 241: 173792, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38806117

RÉSUMÉ

Formosan wood mice (Apodemus semotus) are endemic rodents in Taiwan. Recently Formosan wood mice exhibit similar locomotor behaviors in the laboratory environment as in the field environment has shown. Contemporaneously, Formosan wood mice have higher moving distances of and central dopaminergic (DAergic) activities than C57BL/6 mice in behavioral test. This study tried to compare the behavioral responses between male Formosan wood mice and male C57BL/6 mice in the light-dark exploration tests. We also measured the levels of DA and 3,4-dihydroxyphenylacetic acid (DOPAC), the primary metabolite of DA, to assess the dopaminergic activity of the medial prefrontal cortex, striatum, and nucleus accumbens. Our data show that Formosan wood mice revealed higher exploration and central DAergic activities than did C57BL/6 mice in the light-dark exploration tests, and diazepam (an anxiolytics) treatment reduced the exploratory activity and central dopaminergic activities in Formosan wood mice, but not in C57BL/6 mice. After repeated exposure to light-dark exploration tests, the latency to dark zone was increased, and the duration in light zone as well as the central DAergic activity were decreased in C57BL/6 mice. This study provides comparative findings; Formosan wood mice showed the higher exploratory activities than C57BL/6 mice did, and their central DAergic activities were related to the behavioral responses in these two mice. This could potentially shed light on the reasons behind the prevalence of higher exploration and central dopaminergic activities. Using Formosan wood mice as a model to study human diseases related to hyperactivity adds significant value to the potential research.


Sujet(s)
Comportement animal , Dopamine , Comportement d'exploration , Souris de lignée C57BL , Murinae , Animaux , Mâle , Souris , Dopamine/métabolisme , Comportement d'exploration/effets des médicaments et des substances chimiques , Comportement animal/effets des médicaments et des substances chimiques , Acide 3,4-dihydroxy-benzèneacétique/métabolisme , Diazépam/pharmacologie , Anxiolytiques/pharmacologie , Noyau accumbens/métabolisme , Noyau accumbens/effets des médicaments et des substances chimiques , Cortex préfrontal/métabolisme , Cortex préfrontal/effets des médicaments et des substances chimiques , Corps strié/métabolisme , Corps strié/effets des médicaments et des substances chimiques , Activité motrice/effets des médicaments et des substances chimiques
12.
Biomed Pharmacother ; 176: 116771, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38795639

RÉSUMÉ

Anxiety-like conditions can interfere with daily activities as the adaptive mechanism fails to cope with stress. These conditions are often linked with increased oxidative stress, and abrupt neurotransmission and electroencephalography (EEG) wave pattern. Geraniol, a monoterpenoid, has antioxidant and anti-inflammatory activities, as well as brain-calming effects. Therefore, in this study, geraniol was tested for the potential anxiolytic effects in a rat model of anxiety. The rats were exposed to an electric foot shock (1 mA for 1 s) to develop anxiety-like symptoms. Treatment was carried out using geraniol (10 and 30 mg/kg) and the standard diazepam drug. The behavior of the rats was analyzed using the open field test, light-dark test, and social interaction test. Afterward, the rats were decapitated to collect samples for neurochemical and biochemical analyses. The cortical-EEG wave pattern was also obtained. The study revealed that the electric foot shock induced anxiety-like symptoms, increased oxidative stress, and altered hippocampal neurotransmitter levels. The power of low-beta and high-beta was amplified with the increased coupling of delta-beta waves in anxiety group. However, the treatment with geraniol and diazepam normalized cortical-EEG wave pattern and hippocampal serotonin and catecholamines profile which was also reflected by reduced anxious behavior and normalized antioxidant levels. The study reports an anxiolytic potential of geraniol, which can be further explored in future.


Sujet(s)
Monoterpènes acycliques , Anxiolytiques , Anxiété , Comportement animal , Électroencéphalographie , Hippocampe , Stress oxydatif , Rat Wistar , Transmission synaptique , Animaux , Monoterpènes acycliques/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Anxiété/traitement médicamenteux , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Anxiolytiques/pharmacologie , Rats , Transmission synaptique/effets des médicaments et des substances chimiques , Comportement animal/effets des médicaments et des substances chimiques , Électrochoc , Antioxydants/pharmacologie , Terpènes/pharmacologie , Diazépam/pharmacologie , Modèles animaux de maladie humaine , Ondes du cerveau/effets des médicaments et des substances chimiques
13.
Metab Brain Dis ; 39(5): 731-739, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38720093

RÉSUMÉ

Brain function is highly altered by glucose toxicity related to diabetes. High consumption of sugar in normal conditions is suspected to affect as well brain integrity. The present study investigates the possible effects of short-term exposure to high sugar diet on brain redox homeostasis in healthy mice. Male adult healthy mice were divided into two groups: control (CG) and sugar-exposed group (SG), that was exposed continually to 10% of glucose in drinking water for 7 days and 20% sucrose pellets food. Behavior, blood glucose variability and cerebral cortex oxidative stress biomarkers were measured at the end of exposure. Animals exposed to the high sugar diet expressed a significant increase in blood glucose levels and high glucose variability compared to control. These animals expressed as well anxiolytic behavior as revealed by the plus maze test. Exposure to the sugar diet altered redox homeostasis in the brain cortex as revealed by an increase in lipid peroxidation and the activity of antioxidant enzymes superoxide dismutase (SOD) and glutathione-s-transferase (GST). On the other hand, catalase (CAT) activity was decreased, and reduced glutathione (GSH) level was not altered compared to control. Further studies are required to understand the mechanisms trigging oxidative stress (OS) in the brain in response to short term exposure to high sugar diet and glucose fluctuations.


Sujet(s)
Glycémie , Cortex cérébral , Stress oxydatif , Animaux , Stress oxydatif/effets des médicaments et des substances chimiques , Cortex cérébral/métabolisme , Cortex cérébral/effets des médicaments et des substances chimiques , Mâle , Souris , Glycémie/métabolisme , Peroxydation lipidique/effets des médicaments et des substances chimiques , Anxiété/métabolisme , Anxiolytiques/pharmacologie , Catalase/métabolisme , Glutathion/métabolisme , Superoxide dismutase/métabolisme , Glucose/métabolisme
14.
Neurol Res ; 46(8): 752-762, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38719201

RÉSUMÉ

BACKGROUND: Anxiety is an adaptive response to potentially threatening conditions. Excessive and uncontrolled anxiety responses become nonadaptive and cause anxiety disorders. To better understand the anxiety-modulating effects of Mg sulfate, behavioral test batteries in the assessment of anxiety and learning and memory functions were performed simultaneously over a time period. This study also examines the effects of Mg sulfate compared to diazepam, an anxiolytic drug with amnestic effects on anxiety-like behavior, as well as possible oxidative-nitrosative stress and hippocampal changes in male rats exposed to predator odor. METHODS: Young adult Sprague-Dawley male rats were used. The rats were assessed using a comprehensive neurobehavioral test battery consisting of novel object recognition, open field, and successive alleys tasks. Anxiety was induced by cat odor, and diazepam and Mg were used as study drugs. Of the frontal cortex and hippocampus, the state of total oxidant and antioxidant and NO levels and histological examination of hippocampal CA1, CA2, CA3, and DG regions were performed. RESULTS: Diazepam- and Mg-treated rats showed an improvement in anxiety-related behavior to predator odors. Furthermore, Mg treatment alleviated some of the increasing oxidative stress in the frontal cortex and hippocampus of rats, while diazepam treatment in particular enhanced hippocampal oxidant and antioxidant activity. In addition, brain NO increase induced by animal odor exposure or diazepam treatment was ameliorated by Mg administration. CONCLUSIONS: Overall, our work suggests that Mg had a partial anxiolytic effect on anxiety-like behaviors, although not as much as diazepam, and this effect varied depending on the dose. Mg treatment might counteract increased oxidative stress and elevated NO levels in the brain.


Sujet(s)
Anxiolytiques , Anxiété , Diazépam , Modèles animaux de maladie humaine , Sulfate de magnésium , Rat Sprague-Dawley , Animaux , Mâle , Anxiété/traitement médicamenteux , Diazépam/pharmacologie , Anxiolytiques/pharmacologie , Anxiolytiques/usage thérapeutique , Sulfate de magnésium/pharmacologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Rats , Mémoire/effets des médicaments et des substances chimiques , Monoxyde d'azote/métabolisme , Odorisants
15.
Nature ; 630(8015): 237-246, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38720072

RÉSUMÉ

Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1-3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine hallucinogens5, particularly 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a psychedelic found in the toxin of Colorado River toads6. Although 5-HT1A is a validated therapeutic target7,8, little is known about how psychedelics engage 5-HT1A and which effects are mediated by this receptor. Here we map the molecular underpinnings of 5-MeO-DMT pharmacology through five cryogenic electron microscopy (cryo-EM) structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis and mouse behaviour. Structure-activity relationship analyses of 5-methoxytryptamines at both 5-HT1A and 5-HT2A enable the characterization of molecular determinants of 5-HT1A signalling potency, efficacy and selectivity. Moreover, we contrast the structural interactions and in vitro pharmacology of 5-MeO-DMT and analogues to the pan-serotonergic agonist LSD and clinically used 5-HT1A agonists. We show that a 5-HT1A-selective 5-MeO-DMT analogue is devoid of hallucinogenic-like effects while retaining anxiolytic-like and antidepressant-like activity in socially defeated animals. Our studies uncover molecular aspects of 5-HT1A-targeted psychedelics and therapeutics, which may facilitate the future development of new medications for neuropsychiatric disorders.


Sujet(s)
5-Méthoxy-tryptamine , Anxiolytiques , Antidépresseurs , Méthoxy-diméthyl-tryptamine , Récepteur de la sérotonine de type 5-HT1A , Récepteur de la sérotonine de type 5-HT2A , Animaux , Humains , Mâle , Souris , 5-Méthoxy-tryptamine/analogues et dérivés , 5-Méthoxy-tryptamine/composition chimique , 5-Méthoxy-tryptamine/pharmacologie , 5-Méthoxy-tryptamine/usage thérapeutique , Anxiolytiques/composition chimique , Anxiolytiques/pharmacologie , Anxiolytiques/usage thérapeutique , Antidépresseurs/composition chimique , Antidépresseurs/pharmacologie , Antidépresseurs/usage thérapeutique , Cryomicroscopie électronique , Hallucinogènes , Lysergide/composition chimique , Lysergide/pharmacologie , Méthoxy-diméthyl-tryptamine/composition chimique , Méthoxy-diméthyl-tryptamine/pharmacologie , Méthoxy-diméthyl-tryptamine/usage thérapeutique , Modèles moléculaires , Récepteur de la sérotonine de type 5-HT1A/composition chimique , Récepteur de la sérotonine de type 5-HT1A/génétique , Récepteur de la sérotonine de type 5-HT1A/métabolisme , Récepteur de la sérotonine de type 5-HT1A/ultrastructure , Récepteur de la sérotonine de type 5-HT2A/composition chimique , Récepteur de la sérotonine de type 5-HT2A/génétique , Récepteur de la sérotonine de type 5-HT2A/métabolisme , Récepteur de la sérotonine de type 5-HT2A/ultrastructure , Agonistes des récepteurs de la sérotonine/composition chimique , Agonistes des récepteurs de la sérotonine/pharmacologie , Agonistes des récepteurs de la sérotonine/usage thérapeutique , Relation structure-activité
16.
Pak J Pharm Sci ; 37(2): 349-356, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38767102

RÉSUMÉ

Evidence suggests that surgical procedures can effect the central nervous system and lead to changes in mood and behavior, rarely understood about the role of acute inflammation in promoting acute anxiety postoperatively. This study was designed to explore the possible mechanism of dexmedetomidine (DEX, a2-adrenergic receptor agonist) for reducing acute postoperative anxiety, which may be related to the activation of nuclear factor kappa B (NF-κB) and downstream signal pathway in the hippocampus. Experiments were conducted with rat, the elevated plus-maze and open field test were performed to evaluate anxiety-like behavior. Inhibit DEX with Atipamezole (AT, α2-adrenergic receptor antagonist) and inhibit NF-κB with Pyrrolidinedithiocarbamate (PDTC, inhibit phosphorylation of IκB, prevent the activation of NF-κB), the level of interleukin-6 (IL-6), IL-1ß, IL-10 and Tumor necrosis factor-α (TNF-α); the nuclear translocation of NF-κB in the hippocampus and anxiety-like behavior were measured. Rats exhibited anxiety-like behavior at 6h and 12h after surgery. Preoperative administration of DEX significantly alleviated postoperative anxiety-like behavior. DEX premedication inhibited the nuclear translocation of NF-κB alleviate acute postoperative anxiety. These findings are the first to show that acute postoperative anxiety may be related to NF-κB nuclear translocation in the hippocampus in rats, which can be alleviated by DEX premedication.


Sujet(s)
Anxiété , Dexmédétomidine , Hippocampe , Facteur de transcription NF-kappa B , Rat Sprague-Dawley , Transduction du signal , Animaux , Dexmédétomidine/pharmacologie , Facteur de transcription NF-kappa B/métabolisme , Mâle , Anxiété/traitement médicamenteux , Anxiété/psychologie , Transduction du signal/effets des médicaments et des substances chimiques , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Rats , Agonistes des récepteurs alpha-2 adrénergiques/pharmacologie , Comportement animal/effets des médicaments et des substances chimiques , Anxiolytiques/pharmacologie , Cytokines/métabolisme , Modèles animaux de maladie humaine , Imidazoles
17.
Bioorg Chem ; 148: 107435, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38762999

RÉSUMÉ

BACKGROUND: Pyridine and its derivatives play a vital role in medicinal chemistry, serving as key scaffolds for drugs. The ability to bind to biological targets makes pyridine compounds significant, sparking interest in creating new pyridine-based drugs. Thus, the purpose of the research is to synthesize new thioalkyl derivatives of pyridine, predict their biological spectrum, study their psychotropic properties, and based on these findings, perform structure-activity relationships to assess pharmacophore functional groups. METHODS: Classical organic methods were employed for synthesizing new thioalkyl derivatives of pyridine, with a multifaceted pharmacological profiles. Various software packages and methods were employed to evaluate the biological spectrum of the newly synthesized compounds. For the evaluation of neurotropic activity of new synthesized compounds, some biological methods were used according to indicators characterizing anticonvulsant, sedative and antianxiety activity as well as side effects. RESULTS: Effective synthetic methods for 6-amino-4-phenyl-2-thio-2H-thiopyran-5-carboxylic acid ethyl ester, 2-amino substituted thiopyridine derivatives and 6-cycloamino-2-thioalkyl-4-phenylnicotinate derivatives were obtained in high yield. Predicted biological spectra and pharmacokinetic data indicated high gastrointestinal absorption and low blood-brain barrier passage for most compounds and demonstrated potential various biological effects, particularly psychotropic properties. Studied compounds demonstrated high anticonvulsant activity through antagonism with pentylenetetrazole. They exhibited low toxicity without inducing muscle relaxation in the studied doses. In psychotropic studies, the compounds displayed activating, sedative, and anxiolytic effects. Notably, the 6-amino-2-thioalkyl-4-phenylnicotinate derivatives demonstrated significant anxiolytic activity (about four times more compared to diazepam). They also exhibited pronounced sedative effects. Ethyl 2-({2-[(diphenylmethyl)amino]-2-oxoethyl}thio)-4-phenyl-6-pyrrolidin-1-ylnicotinate exhibited anxiolytic activity even two times greater than diazepam. Moreover, all studied compounds showed statistically significant antidepressant effects. Noteworthy ethyl 2-({2-oxo-2-[(tetrahydrofuran-2-ylmethyl)amino]ethyl}thio)-4-phenyl-6-pyrrolidin-1-ylnicotinate showcasing its unique psychotropic effect. CONCLUSIONS: The selected compounds demonstrate anticonvulsant properties, activating behavior, and anxiolytic effects, while simultaneously exhibiting antidepressant effects and these compounds as promising candidates for further exploration in the development of therapeutics with a broad spectrum of neuropsychiatric applications.


Sujet(s)
Anxiolytiques , Anticonvulsivants , Pyridines , Relation structure-activité , Pyridines/composition chimique , Pyridines/pharmacologie , Pyridines/synthèse chimique , Animaux , Anticonvulsivants/synthèse chimique , Anticonvulsivants/pharmacologie , Anticonvulsivants/composition chimique , Souris , Anxiolytiques/pharmacologie , Anxiolytiques/synthèse chimique , Anxiolytiques/composition chimique , Structure moléculaire , Relation dose-effet des médicaments , Mâle , Crises épileptiques/traitement médicamenteux , Hypnotiques et sédatifs/pharmacologie , Hypnotiques et sédatifs/synthèse chimique , Hypnotiques et sédatifs/composition chimique , Pentétrazol
18.
J Ethnopharmacol ; 332: 118395, 2024 Oct 05.
Article de Anglais | MEDLINE | ID: mdl-38801915

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Rosmarinus officinalis L. (Rosemary) is a popular herb with reported effectiveness against diarrhea, anxiety and constipation, albeit with limited pharmacological evidence. AIM OF THE STUDY: The current study was aimed at evaluating the therapeutic potential, possible pharmacological mechanisms of action and active constituents of hydro-ethanolic extract of rosemary (Rs.Cr), as potential anti-diarrheal, laxative and anxiolytic agent. METHOD: Rs.Cr was analyzed through reverse-phase high pressure liquid chromatography (RP-HPLC). Laxative, antidiarrheal, and anxiolytic activities were assessed using in vivo models. Spasmogenic and spasmolytic mechanisms were studied on isolated guinea pig ileum and rabbit jejunum tissues, respectively. Possible role of diosmetin, one of the active constituents of Rs.Cr was also evaluated. RESULTS: RP-HPLC analysis revealed presence of diosmetin, rutin and apigenin in Rs.Cr. Laxative effect was seen at low doses, which was partially reversed in atropinized mice. The spasmogenic mechanism was mediated by cholinergic and histaminergic receptors stimulation. At higher doses, antidiarrheal activity was evident, with reduction in gastrointestinal motility and secretions using charcoal meal and enteropooling assays, respectively. Rs.Cr also showed dose-dependent anxiolytic effect. The antispasmodic mechanisms were mediated by anti-muscarinic and K+ channel opening-like effect (predominant KATP-dependent). Diosmetin exhibited antidiarrheal and antispasmodic activities, but spasmogenic effect was not seen. CONCLUSION: Rosemary leaves have dual antidiarrheal and laxative effects, and as well as anxiolytic activity. In addition, the possible modulation of muscarinic and histaminergic receptors, and KATP channels show it as potential herb to be explored for irritable bowel syndrome. Diosmetin is possibly one of its constituents that contributes to its antidiarrheal activity.


Sujet(s)
Anxiolytiques , Motilité gastrointestinale , Iléum , Extraits de plantes , Rosmarinus , Animaux , Cochons d'Inde , Rosmarinus/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Souris , Mâle , Motilité gastrointestinale/effets des médicaments et des substances chimiques , Lapins , Anxiolytiques/pharmacologie , Anxiolytiques/isolement et purification , Anxiolytiques/composition chimique , Iléum/effets des médicaments et des substances chimiques , Iléum/métabolisme , Iléum/physiologie , Antidiarrhéiques/pharmacologie , Antidiarrhéiques/isolement et purification , Flavonoïdes/pharmacologie , Parasympatholytiques/pharmacologie , Parasympatholytiques/isolement et purification , Laxatifs/pharmacologie , Laxatifs/isolement et purification , Jéjunum/effets des médicaments et des substances chimiques , Jéjunum/métabolisme , Diarrhée/traitement médicamenteux , Femelle
19.
J Ethnopharmacol ; 331: 118332, 2024 Sep 15.
Article de Anglais | MEDLINE | ID: mdl-38735421

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Citri Reticulata Pericarpium Viride (also known Qing-Pi or QP) is a plant in the Rutaceae family, QP is a traditional Qi-regulating medicine in Chinese medicine that is compatible with other Chinese medicine components and has extensive clinical practice in treating anxiety and depression. Reports on the pharmacological effects of QP have demonstrated its neuroprotective effects and antioxidant capacities. Numerous pharmacological benefits of QP are attributed to its antioxidant abilities. Anxiety disorders are a broadly defined category of mental illnesses. Oxidative stress and an imbalance in the antioxidant defense system are typical pathological features of these disorders. AIM OF THE STUDY: The aim of this study was to evaluate the effects of QP essential oil on anxiety using animal models and investigate the underlying neurobiological mechanisms. MATERIALS AND METHODS: This study aimed to develop an animal model of anxiety using chronic restraint stress and investigate the effects of inhalation of Citri Reticulata Pericarpium Viride essential oil on anxiety-like behavior, olfactory function, and olfactory bulb neurogenesis in mice with anxiety. RESULTS: The results showed that long-term chronic restraint stimulation caused a decrease in olfactory function, significant anxiety-like behavior, and a notable reduction in the number of neurons in the olfactory bulb. However, inhalation of Citri Reticulata Pericarpium Viride essential oil reversed these effects, improving the olfactory function, neuro-stimulating effect, alleviating anxiety-like behavior, and regulating theta (4-12Hz) oscillation in the hippocampus DG area. These effects were associated with changes in the expression levels of glutamate receptor NMDAR and NeuN in olfactory bulb. CONCLUSIONS: The study revealed that mice with anxiety induced by chronic restraint stress exhibited significant olfactory dysfunction, providing strong evidence for the causal relationship between anxiety disorders and olfactory dysfunction. Moreover, QP essential oil has the potential to be developed as a therapeutic drug for anxiety disorders, in addition to its role as a complementary anxiolytic.


Sujet(s)
Anxiolytiques , Anxiété , Huile essentielle , Bulbe olfactif , Récepteurs du N-méthyl-D-aspartate , Animaux , Huile essentielle/pharmacologie , Huile essentielle/isolement et purification , Mâle , Anxiété/traitement médicamenteux , Souris , Anxiolytiques/pharmacologie , Anxiolytiques/usage thérapeutique , Anxiolytiques/isolement et purification , Récepteurs du N-méthyl-D-aspartate/métabolisme , Comportement animal/effets des médicaments et des substances chimiques , Acide glutamique/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Stress psychologique/traitement médicamenteux
20.
Drug Res (Stuttg) ; 74(5): 220-226, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38729181

RÉSUMÉ

Combinations of medications are frequently employed when their effects are similar. Beyond aiding in the reduction of medication dosages, this approach may yield additional positive outcomes. Studies have shown that zinc can mitigate anxiety-related behavior in laboratory animals. This study aimed to investigate the potential stabilizing effects of zinc chloride and diazepam in Wistar albino rats.Five groups, each comprising six animals. Test groups included two combinations of zinc chloride and diazepam, each with two different doses of diazepam (1 and 2 mg/kg) and 10 mg/kg of zinc chloride. Four established anxiety models-the Elevated Plus Maze (EPM), the hole board, the light and dark box, and the mirror chamber-were employed to assess the anxiolytic effects. The combination of zinc chloride and diazepam proved to be more effective than the individual doses of zinc chloride and diazepam, indicating enhanced anxiolytic effects.


Sujet(s)
Anxiolytiques , Anxiété , Comportement animal , Chlorures , Diazépam , Synergie des médicaments , Rat Wistar , Composés du zinc , Animaux , Anxiolytiques/pharmacologie , Anxiolytiques/administration et posologie , Diazépam/pharmacologie , Composés du zinc/pharmacologie , Composés du zinc/administration et posologie , Rats , Anxiété/traitement médicamenteux , Mâle , Comportement animal/effets des médicaments et des substances chimiques , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Association de médicaments , Relation dose-effet des médicaments
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...